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A B S T R A C T
Disulﬁram, a clinically used alcohol-deterrent has gained prominence as a potential anti-cancer agent
due to its impact on copper-dependent processes. Few studies have investigated zinc effects on
disulﬁram action, despite it having high afﬁnity for this metal. Here we studied the cytotoxic effects of
disulﬁram in breast cancer cells, and its relationship with both intra and extracellular zinc. MCF-7 and
BT474 cancer cell lines gave a striking time-dependent biphasic cytotoxic response between 0.01 and
10 mM disulﬁram. Co-incubation of disulﬁram with low-level zinc removed this effect, suggesting that
availability of extracellular zinc signiﬁcantly inﬂuences disulﬁram efﬁcacy. Live-cell confocal
microscopy using ﬂuorescent endocytic probes and the zinc dye Fluozin-3 revealed that disulﬁram
selectively and rapidly increased zinc levels in endo-lysosomes. Disulﬁram also caused spatial
disorganization of late endosomes and lysosomes, suggesting they are novel targets for this drug. This
relationship between disulﬁram toxicity and ionophore activity was consolidated via synthesis of a new
disulﬁram analog and overall we demonstrate a novel mechanism of disulﬁram-cytotoxicity with
signiﬁcant clinical implications for future use as a cancer therapeutic.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Many current cancer therapies are limited by the severity and
frequency of adverse side effects and there is high demand for non-
toxic alternatives. One source of new therapies may be through
repurposing of clinically approved drugs, where safety in patients
has already been demonstrated. Disulﬁram has a long medical
history as an alcohol deterrent, however more recently has
demonstrated anti-cancer effects in a range of solid and
hematological malignancies [1]. The biological activity of disulﬁ-
ram is attributed to its ability to bind divalent cations and
consequently disrupt metal dependent processes, particularly
those involving copper and zinc [2,3]. Observations that both these
metal ions are involved in oncogenic development have led to
increased interest in the anti-cancer potential of this drug [4]. As
part of a copper complex, disulﬁram has been reported to induce
apoptosis in both cultured breast cancer cells and xenografts
through proteasomal inhibition [5–7]. These complexes have also
been shown to stabilize the NFkB inhibitor protein, IkB, thus* Corresponding author.
E-mail address: jonesat@cardiff.ac.uk (A.T. Jones).
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0006-2952/ 2015 The Authors. Published by Elsevier Inc. This is an open access articre-sensitizing gemcitabine resistant tumors with enhanced NFkB
signaling [8]. In a case study of a patient with stage IV ocular
melanoma with liver metastases, combination therapy involving
disulﬁram and zinc gluconate was able to induce remission with
almost no side effects [9]. These observations have led to its
introduction to clinical trials, including one involving patients with
hepatic malignancies treated with disulﬁram and copper gluconate
(NCT00742911, University of Utah). Additionally, disulﬁram
treatment has been reported to remove essential copper and zinc
ions from enzymes that regulate extracellular matrix degradation
and oxygen metabolism resulting in suppression of cancer invasion
and angiogenesis in vitro and in vivo [2,3].
Much of the current literature surrounding disulﬁram focuses
on its capacity to bind copper ions, via two metal binding regions
in its structure (Fig. 1A). Relatively little has been done to
determine the role of zinc in its anti-cancer properties despite the
fact that it also has high afﬁnity for this metal [3]. Studies have
highlighted the role of zinc in the etiology of breast cancer where
high expression of zinc transporter proteins such as ZIP7 and ZIP10,
in breast cancer cell models increases intracellular zinc levels and
is associated with endocrine therapy resistance and increased
invasiveness [10,11]. Additionally, zinc has been reported to
increase pro-survival signaling [12] and inhibit caspases [13] inle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Structure of disulﬁram and the disulﬁram analog FS03EB. (A) *Indicates metal
binding regions within the structure. (B) 1H NMR (500 MHz, CDCl3) d 1.30 (3H, bs,
CH3), 1.47 (3H, s, CH3), 4.05 (4H, bs, CH2CH3), 5.26 (2H, s, CH2Ph), 5.41 (2H, s,
CH2Ph), 7.39 (10H, m, ArH);
13C NMR (125 MHz, CDCl3) d 11.12 (CH3), 13.20 (CH3),
47.18 (CH2), 52.04 (CH2), 55.80 (CH2), 59.54 (CH2), 127.48 (ArCH), 127.72 (ArCH),
128.20 (ArCH), 128.49 (ArCH), 128.79 (ArCH), 128.99 (ArCH), 134.57 (ArC), 135.24
(ArC), 198.82 (C5S), 195.33 (C5S); MS (EI+) m/z 420.08 (M+); HR-MS (ESI+) m/z
[M+H]+ calculated 421.0895, found 421.0896.
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promote cancer cell survival. Paradoxically, high intracellular zinc
is also associated with oxidative toxicity, implying that the cell
maintains tight homeostatic control of this metal and that drugs
which dysregulate this ﬁne balance may induce toxicity [14]. As
the concentration of zinc is higher in cancerous compared to non-
cancerous breast tissue [15] it is possible that drugs which alter
intracellular zinc levels would be selectively toxic to cancer cells.
In this study we investigate the role of both intra and
extracellular zinc in the anti-cancer activity of disulﬁram. We
demonstrate the effect of zinc and copper on the cytotoxicity of the
drug across a panel of cancerous and non-cancerous breast cell
lines. We describe a novel mechanism of action for disulﬁram, via
its ability to rapidly increase intracellular zinc levels in endo-
lysosomal compartments and alter the subcellular localization
speciﬁcally of late lysosomal structures. Both these effects
potentially impact on lysosome function. Interestingly, zinc levels
in a non-cancerous breast cell line remain unaltered by disulﬁram
treatment and taken in the context of the literature surrounding
zinc dysregulation in breast cancer, our results demonstrate a
selective effect of disulﬁram that may have signiﬁcant clinical
implications for its future clinical use.
2. Materials and methods
2.1. Chemicals and reagents
Disulﬁram, diethyldithiocarbamate (DDC), sodium pyrithione,
DMSO, Na-HEPES, NH4Cl, Triton X-100, BSA, ZnCl2, CuCl2, cholera
toxin, insulin, epidermal growth factor, and hydrocortisone were
obtained from Sigma–Aldrich (Dorset, UK). Disulﬁram, DDC, and
sodium pyrithione were dissolved in DMSO to produce a stock
concentration of 10 mM and stored at 20 8C. CellTiter blue
viability reagent was purchased from Promega (Southampton, UK).
Anti-EEA1 (#6104490), anti-LAMP2 (#H4B4), and anti-LC3B
(#2775) antibodies were obtained from BD Bioscience (Oxford,
UK), Developmental Studies Hybridoma Bank (Iowa, USA) and Cell
Signaling Technology (MA, USA) respectively. RPMI, FBS, DMEM/
F12, horse serum, Fluozin-3, Hoechst 33342, dextran-Alexa
647 (10 kDa), Alexa-488 (A-11001) and Alexa-546 (A-11010)conjugated anti-mouse and anti-rabbit antibodies were from Life
Technologies (Paisley, UK).
2.2. Synthesis of disulﬁram analog
FS03EB (bis(N-benzylethylthiocarbamoyl)disulphide; Fig. 1B)
was synthesized according to the method of Liang et al. [16]. Brieﬂy,
N-benzylethylamine and carbon disulphide (2:1 molar ratio) were
mixed together in the presence of carbon tetrabromide (one
equivalent) in dimethylformamide as solvent at room tempera-
ture. Following puriﬁcation by column chromatography, the
identity and purity of the product was conﬁrmed using NMR
spectroscopy and mass spectrometry [17]. FS03EB was then
dissolved in DMSO to produce a stock concentration of 10 mM.
2.3. Cell culture
MDA-MB-231, MCF-7, T47D, and BT474 were maintained in
RPMI 1640 supplemented with 10% FBS. MCF-10A cells were
maintained in DMEM/F12 supplemented with 5% horse serum,
100 ng/ml cholera toxin, 10 mg/ml insulin, 20 ng/ml epidermal
growth factor, and 500 ng/ml hydrocortisone [18]. Herein these are
respectively termed complete media. All cell lines were obtained
from ATCC and routinely tested for mycoplasma infection.
2.4. Viability assays
To account for different growth rates, cells were seeded in black
96-well plates at densities that provided 70% conﬂuency after 72 h.
After a minimum of 24 h, cells were treated with disulﬁram,
disulﬁram metabolite DDC, FS03EB or DMSO  copper or zinc
supplements for the indicated time points. Viability studies were
conducted using the CellTiter Blue assay according to manufacturer’s
protocol. All viability studies were conducted in complete media.
2.5. Live cell imaging of intracellular zinc
Microscopy analysis was conducted on a Leica SP5 confocal
inverted microscope equipped with a 488 nm laser and 40
objective using Leica LAS AF software. For this, cells were
preloaded with 5 mM Fluozin-3 diluted in cell imaging media
(phenol red free RPMI media supplemented with 10% FBS and
50 mM Na-HEPES pH 7.4) for 30 min, before being washed thrice
with PBS which was then replaced with 1 ml cell imaging media. In
live cells representative region of interest was captured before and
subsequent to addition of a 1 ml solution of 10 mM disulﬁram,
sodium pyrithione (positive control) or diluent control. Images are
displayed as a multiple projection of 10 z-planes through the cells.
2.6. Flow cytometry
Cells were preloaded with Fluozin-3 for 30 min as above and
treated with disulﬁram, DDC, FS03EB, sodium pyrithione or diluent
control in cell imaging media or serum free imaging media (phenol
red free RPMI supplemented with 50 mM Na-HEPES pH 7.4)
20 mM zinc or copper for 10 min. Following trypsinization, cells
were resuspended in PBS, and centrifuged three times at
150  g. Cells were then resuspended in media, and 10,000 events
were analyzed via ﬂow cytometry using a BD Biosciences FACSVerse
system equipped with a 488 nm laser.
2.7. Comparative localization of intracellular zinc with endocytic
probes in disulﬁram treated cells
To label the entire ﬂuid-phase endocytic network, MCF-7 cells
were incubated for 4 h with 2.5 mg/ml dextran-Alexa 647 diluted
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342334in cell imaging media. To speciﬁcally label lysosomes, cells were
incubated with dextran-Alexa 647 for 2 h followed by a 4 h chase
[19]. During the ﬁnal stages of this incubation, cells were incubated
with Fluozin-3 for 30 min, washed with PBS, and treated with
10 mM disulﬁram for 10 min. Cells were then washed three times
with PBS, and analyzed via live cell confocal microscopy.
2.8. Localization of endocytic organelles and induction of autophagy
in disulﬁram treated cells
MCF-7 cells were treated with 1 mM disulﬁram or equivalent
diluent control for 3 h (for endosomes and lysosomes) or 24 h
(for autophagosomes) before being washed in PBS, ﬁxed and
permeabilised by either 20 8C methanol for 10 min (for LAMP2)
and LC3B labeling) or with 3% PFA for 15 min, 50 mM NH4Cl for
10 min and 0.2% Triton X-100 for 5 min (for EEA1 labeling).
After ﬁxation the cells were washed three times in PBS,
incubated for 1 h in blocking buffer (2% FBS, 2% BSA in PBS)
then incubated for 1 h with primary antibody diluted 1:200
(LAMP2 and EEA1) or 1:400 (LC3B) in blocking buffer. The
cells were then washed three times in PBS before being
incubated for 1 h with secondary antibodies and Hoechst
33342 (1 mg/ml). Following a further three washes with PBS
they were mounted in oil. Imaging was conducted via confocal
microscopy for LAMP2 and EEA1. For LC3B imaging was
conducted on a Leica DMIRB inverted epi-ﬂuorescent micro-
scope, equipped with a 40 objective.Fig. 2. The cytotoxic proﬁle of disulﬁram in breast cancer cell models. (A) Cells were treat
72 h. (B) MCF-7 cells were imaged using brightﬁeld microscopy following 72 h disulﬁram
with disulﬁram prior to analyzing viability. T-tests were conducted between equivalent ti
treated for 72 h with disulﬁram at concentrations between 1 and 100 mM prior to ana2.9. Statistical testing
For all studies three independent experiments were conducted in
triplicate (for viability studies) or duplicate (for ﬂow cytometry
studies) and signiﬁcance of data determined, as appropriate, using
students two tailed T-test in Microsoft Excel and displayed as
*p < 0.05 or **0.001. Data is presented as the mean and standard error
of the mean. Co-localization via microscopy was determined using
JaCOP plugin of ImageJ and the Pearsons coefﬁcient was used as a
measure of the ratio of pixels which were labeled with dextran-Alexa
647 and Fluozin-3 where 1.0 is complete co-localization [20]. Pear-
son’s coefﬁcient is expressed as standard error of the mean.
3. Results
3.1. Disulﬁram produces a biphasic cytotoxic response in some breast
cancer cell lines
Initial cell viability experiments were conducted to investigate
the sensitivity of a panel of breast cancer cell lines to disulﬁram.
These were chosen to model clinically relevant disease sub types,
including estrogen receptor positive (ER+), human epidermal
growth factor receptor 2 (HER2) negative (MCF-7 and T47D), ER+/
HER2+ (BT474) and ER/HER2 (MDA-MB-231) and the non-
cancerous breast epithelial MCF-10A line. Disulﬁram over 72 h
was only toxic to ER+ cells (MCF-7 and BT474, IC50 0.3 mM vs. MDA-
MB-231 IC50 and MCF-10A IC50 > 10 mM; Fig. 2A), however not alled with a serial dilution of disulﬁram in complete media and viability analyzed after
 (DSF) treatment. Scale bar shows 100 mm. (C) MCF-7 cells were treated for 8–72 h
me points to compare 1 and 10 mM data, *p < 0.05, **p < 0.001. (D) MCF-7 cells were
lyzing viability. Error bars show standard error.
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demonstrating that the presence of ER is not a prerequisite for
sensitivity. In disulﬁram responsive cells (MCF-7 and BT474)
cytotoxicity was biphasic, producing a recovery peak at 10 mM
with almost complete restoration of viability. The biphasic effect in
MCF-7 cells was conﬁrmed by microscopy showing clear
morphological damage at 1 mM that is consistent with loss of
cell viability. These effects were absent at 10 mM where
morphology was comparable to diluent controls; increasing the
disulﬁram concentration to 100 mM then restored the toxic 1 mM
phenotype (Fig. 2B).
To further investigate this biphasic response we determined
whether it was affected by disulﬁram concentration at different
incubation times. MCF-7 cells were treated with 1, 10 and 100 mM
disulﬁram over a range of time points and cell viability was then
determined. Despite an initial cytotoxic phase at <8 h, cell viability
at 10 mM was restored at greater than 24 h (Fig. 2C). For other
concentrations disulﬁram produced a time dependent decrease in
viability; at 1 mM viability steadily decreased between 4 and 72 h
whereas at 100 mM there was a rapid loss of viability to <10%
within 4 h. This data demonstrates that the 10 mM disulﬁram
response is due to recovery from initial effects that are not
manifest as cell death but rather a reduction in metabolic rate as
determined by this assay. When the biphasic peak in MCF-7 cells
was investigated at concentrations between 1 and 100 mM at aFig. 3. Disulﬁram selectively increases intracellular zinc levels in punctate structures of b
(pre-treat) and subsequent to the addition of 10 mM disulﬁram or sodium pyrithione (
equally spaced, single projections and are representative from three independent expesingle 72 h time point, viability was restored to >80% between
5 and 20 mM concentrations of the drug (Fig. 2D).
3.2. Disulﬁram speciﬁcally increases intracellular zinc levels in breast
cancer cells
To investigate the relationship between disulﬁram and
intracellular zinc levels we employed live cell confocal microscopy
using the zinc probe Fluozin-3. In complete media, disulﬁram
rapidly (<10 min) increased intracellular zinc levels in MCF-7 cells,
speciﬁcally to label punctate compartments, to levels comparable
to those obtained using the well established zinc ionophore
sodium pyrithione (Fig. 3). A signiﬁcant proportion of sodium
pyrithione treated cells were also noted for displaying diffuse
cytosolic Fluozin-3 labeling whereas zinc in disulﬁram treated
cells was only observed in punctate structures. Surprisingly, zinc
levels remained unaffected by either disulﬁram or sodium
pyrithione treatment in the non-cancerous MCF-10A cell line.
In order to further investigate the disulﬁram effects seen by
microscopy, a ﬂow cytometry assay was developed to enable
quantitative comparison of intracellular zinc levels in disulﬁram
and sodium pyrithione treated cells. The data supported the
microscopy ﬁndings as 10–100 mM disulﬁram signiﬁcantly
increased intracellular zinc levels in both MCF-7 and MDA-MB-
231 cell lines (Fig. 4A), while zinc levels in MCF-10A cells remainedreast cancer cells. Cells were preloaded with Fluozin-3 for 30 min and imaged before
NaP) in cell imaging media. Images are multiple z-projections from a series of 10
riments. Scale bars show 10 mm.
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Fig. 4. Disulﬁram delivers extracellular zinc into cells rather than releasing intracellular stores. Cells were preloaded with Fluozin-3 and treated with disulﬁram (DSF), DMSO
or sodium pyrithione for 10 min in complete media (A) or serum free media (SFM) 20 mM zinc (B) or copper (C) in MCF-7 cells. Fluozin-3 ﬂuorescence was then determined via
ﬂow cytometry. Error bars show standard error. T-tests in (A) were conducted between DMSO and treatment groups and in (B, C) were conducted between SFM and SFM + Zn/Cu for
each treatment, *p < 0.05, **p < 0.001.
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342336unaffected by the same treatment. To further investigate this, and
minimize the effects of extracellular zinc in serum, the ﬂow
cytometry experiments were conducted in serum free media- low
zinc and copper conditions. Under these conditions, neither
sodium pyrithione nor disulﬁram evoked a statistically signiﬁcant
increase in intracellular zinc in MCF-7 cells (Fig. 4B). Supplemen-
tation of serum free media with 20 mM zinc was sufﬁcient to
completely restore, and in fact exaggerate, the ionophore ability of
both disulﬁram and sodium pyrithione, demonstrating that this
ionophore activity is dependent on extracellular zinc levels. This
effect, with respect to the selectivity of the dye for zinc versus
copper which could possibly also provide Fluozin-3 ﬂuorescence,
was tested by conducting the experiments in serum free media
supplemented with copper. Here copper was unable to signiﬁ-
cantly restore the ﬂuorescence of Fluozin-3 in disulﬁram or sodium
pyrithione treated cells (Fig. 4C), demonstrating that the increased
ﬂuorescence of Fluozin-3 observed in Figs. 3 and 4 was speciﬁcally
due to the effects of zinc.
3.3. Disulﬁram sequesters intracellular zinc in endo-lysosomal
compartments
The observation that disulﬁram sequestered zinc in punctate
structures lead us to investigate the nature of these compartments.
In order to determine whether they were components of the
endocytic network, ﬂuorescent dextran was utilized as anendocytic probe for co-localization studies. By conducting a 2 h
pulse with dextran-Alexa 647 followed by cell washing and a
further 4 h chase, the probe can be trafﬁcked and conﬁned to
lysosomes [19]. Dextran pulse-chase experiments were performed
and cells were co-stained with Fluozin-3 and treated with
disulﬁram; the degree of co-localization between dextran-Alexa
647 and Fluozin-3 was then analyzed using live cell confocal
microscopy. Fig. 5A demonstrates that a signiﬁcant portion of
dextran labeled lysosomes were also labeled with Fluozin-3 and
very few dextran only structures were observed (Pearsons
coefﬁcient = 0.49  0.06 for three independent experiments). When
the entire ﬂuid phase network was labeled with dextran as a single
4 h pulse (Fig. 5B), a higher degree of co-localization was observed
between the two probes (Pearsons coefﬁcient = 0.67  0.04) suggest-
ing that disulﬁram was also driving zinc into earlier compartments of
the endocytic network.
To investigate whether disulﬁram inﬂuences the spatial
organization of these endocytic structures MCF-7 cells were
treated with the drug for 3 h prior to performing immunoﬂuores-
cence analysis using antibodies recognizing the early endosomal
marker, Early Endosome Antigen 1 (EEA1) or the late endosomal/
lysosomal marker, Lysosome Associated Membrane Protein 2
(LAMP2) [21]. Disulﬁram was observed to have no effect on the
localization of early endocytic structures (Fig. 6A), however caused
late endosomes and lysosomes to be redistributed from typical
perinuclear clusters observed in control cells to more diffuse
Fig. 5. Disulﬁram increases intracellular zinc in endo-lysosomal compartments of breast cancer cells. Dextran-Alexa 647 was used to highlight late endo-lysosomal
compartments (A) or the entire ﬂuid phase endocytic network (B) in MCF-7 cells, as described in Section 2. Cells were then incubated with Fluozin-3, treated with 10 mM
disulﬁram for 10 min and co-localization between Fluozin-3 and dextran-Alexa 647 was analyzed via confocal microscopy. Images show single z-projections through the
cells and lower panel in (A) and (B) show a zoomed image of an identiﬁed cell in upper panel. Images shown are representative from three independent experiments. Co-
localization is marked by arrow heads. Scale bars show 10 mm.
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Fig. 6. Disulﬁram causes mislocalization of lysosomes, however does not alter localization of early endosomes or autophagic membranes. MCF-7 cells were treated with 1 mM
disulﬁram or chloroquine (100 mM, 6 h) and then analyzed via immunoﬂuorescence microscopy using antibodies recognizing EEA1 (A), LAMP2 (B) or LC3B (C). Blue nuclei are
labeled with Hoechst 33342. Image shows single projection through the middle of the cell and is representative from three independent experiments. Scale bars show 10 mm.
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342338scattering throughout the cytoplasm (Fig. 6B). The ability of
disulﬁram to induce autophagy was investigated using antibodies
recognizing a marker of autophagic membranes, microtubule-
associated Light Chain 3 B (LC3B). For this experiment cells were
either treated with disulﬁram for 24 h prior to LC3B immunoﬂuo-
rescence analysis, or for 6 h with chloroquine, an agent which
causes accumulated LC3B via stabilization of autophagosomal
membranes [22]. Chloroquine treated cells displayed large LC3B
containing structures representing autophagosomes, however this
phenotype was absent in cells treated with disulﬁram (Fig. 6C).3.4. Supplementation with zinc or copper increases disulﬁram
potency
The interaction between disulﬁram and zinc observed in our
previous results lead us to consider whether enrichment of
complete media with zinc or copper could affect the cytotoxicity of
the drug in cancerous and non-cancerous breast cells. As control
experiments, we initially investigated whether supplementing cell
media with increasing concentrations of zinc or copper in the
absence of disulﬁram had any effect on cell viability. These studies
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342 339demonstrated that 20 mM zinc or copper was without effect but
toxicity was observed at higher concentrations of both metals with
MCF-7 and MCF-10A showing particular sensitivity to copper
(Fig. 7A). When a non-toxic dose of zinc or copper (20 mM) was
given in combination with disulﬁram, cytotoxicity was signiﬁ-
cantly enhanced in all cell lines (Fig. 7B, Table 1). In the case of
MCF-7 cells, the disulﬁram biphasic response was completely
abolished by both zinc and copper supplementation, however0
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Fig. 7. Zinc and copper enhance the cytotoxicity of disulﬁram. (A) Cells were treated with
before cell viability analysis was performed. (B) Cells were treated with disulﬁram 20 m
and D) Viability of MCF-7 cells treated with disulﬁram  zinc or copper in supplemented in
data in Fig. 7B are provided in Table 1.cytotoxicity of disulﬁram at lower concentrations was reduced by
addition of either metal supplement. The minimum concentration
of copper and zinc supplement required to inﬂuence cell recovery
(biphasic peak) in MCF-7 cells was then determined and data in
Fig. 7C and D shows that 2.0 mM zinc and 0.125 mM copper
signiﬁcantly reduced the ability of the cells to recover from
disulﬁram effects. At higher concentrations both metals complete-
ly reversed the biphasic response.0
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Table 1
Co-incubation of copper/zinc signiﬁcantly altered the cytotoxico proﬁle of disulﬁram.
MCF-7 MDA-MB-231 MCF-10A
[DSF] 0.1 mM 1 mM 10 mM 100 mM 0.1 mM 1 mM 10 mM 100 mM 0.1 mM 1 mM 10 mM 100 mM
DSF alone 54.5  10.5 30.2  7.5 82.2  8.7 0.1  0.2 91.6  2.8 77.0  10.8 74.0  12.3 0.02  0.1 95.5  1.6 99.8  1.6 100.3  2.9 2.4  1.2
DSF + Zn 95.8  4.2** 44.6  3.5* 0.1  0.2** 0.1  0.3 89.1  4.6 63.9  9.3 0.1  0.1** 0.02  0.1 93.3  3.9 94.3  2.9 0.3  0.1** 0.3  0.1
DSF + Cu 92.8  9.8* 0.6  0.2** 1.0  0.4** 0.7  0.2* 98.5  2.2 27.9  12.5* 0.7  0.1** 1.0  0.2* 95.7  9.5 110.7  7.1 0.16  0.1** 0.3  0.1
Breast cells were treated with the indicated concentrations of disulﬁram 20 mM zinc or copper for 72 h prior to performing viability analysis. Values displayed are percentage
viability and standard error of the mean. T-tests were conducted between disulﬁram treatment alone and disulﬁram + zinc/copper.
* p < 0.05
** p < 0.001.
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structural analog correlates with ionophore activity
Disulﬁram in vitro and in vivo is rapidly metabolized to give two
molecules of DDC [23]. The possibility that this major metabolite
was able to induce toxicity and also act as a zinc ionophore was
also investigated in MCF-7 cells. DDC displayed a sharp increase in
toxicity at concentrations higher than 0.1 mM with evidence of
recovery being observed at 100 mM, rather than at 10 mM as in the
case of disulﬁram (compare Fig. 8A and 2A). Supplementation with
copper and zinc completely ablated the DDC biphasic effects
(Fig. 8A) and signiﬁcantly enhanced its toxicity (Table 2). The
metabolite was also able to increase intracellular zinc levels (Fig. 8B)
but was a less potent zinc ionophore compared with the parent drug
(Fig. 4A).
To determine how cytotoxicity may relate to the capacity of
disulﬁram and DDC to deliver zinc, a close structural analog ofA.
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Fig. 8. Toxicity of DDC and FS03EB correlates with zinc ionophore activity. (A, C) MCF-7 ce
for 72 h prior to performing viability analysis. (B, D) MCF-7 cells were preloaded with Fluo
Fluozin-3 ﬂuorescence via ﬂow cytometry. Error bars show standard error. *p < 0.05, p-vadisulﬁram, FS03EB, was synthesized and viability assays were
performed with this compound. FS03EB lacked any signiﬁcant
toxicity at concentrations below 100 mM in complete media and a
biphasic response was not observed (Fig. 8C). Here, the core zinc
binding thiuram disulﬁde pharmacophore was retained, but two
of the terminal ethyl groups were replaced by the related benzyl
group (see Fig. 1B for chemical structure and physical characteri-
zation of FS03EB). In complete media, and contrary to the effects
observed with disulﬁram and DDC, data in Fig. 8D show that
FS03EB was unable to signiﬁcantly increase intracellular zinc
levels. However, co-incubation of this compound (>1 mM) with
20 mM zinc or copper was toxic leading to complete loss of
viability at 1 mM and 10 mM for copper and zinc respectively
(Table 2). When the zinc ionophore activity of FS03EB was
investigated in conditions which induced toxicity (complete
media + 20 mM zinc), it resulted in a >3-fold increase in Fluozin-3
ﬂuorescence.0
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lls were treated with DDC (A) or FS03EB (C) 20 mM copper or zinc in complete media
zin-3, treated with DDC (B) or FS03EB 20 mM zinc (D) for 10 min prior to measuring
lues for data in (A and C) are provided in Table 2.
Table 2
Co-incubation of copper/zinc signiﬁcantly altered the cytotoxic proﬁle of DDC and FS03EB.
[DDC] [FS03EB]
0.1 mM 1 mM 10 mM 100 mM 0.1 mM 1 mM 10 mM 100 mM
No supplement 81.7  15.1 15.3  2.1 29.3  11.1 56.4  11.0 98.9  3.1 92.4  5.4 76.4  1.1 0.7  0.4
Zn supplement 99.5  2.4** 38.8  7.1** 21.1  7.6 0.7  0.1** 104.4  4.6 88.2  9.3 1.1  0.2** 0.7  0.2
Cu supplement 89.5  4.4 17.3  4.3 7.2  2.8 9.7  4.1* 63.4  1.9* 1.5  0.2** 0.8  0.2** 0.8  0.1
MCF-7 cells were treated with DDC or FS03EB 20 mM zinc or copper for 72 h prior to performing viability analysis. Values displayed are percentage viability and standard error of
the mean. Student two-tailed T-tests were conducted between DDC or FS03EB treatment alone and FS03EB or DDC + zinc/copper.
* p < 0.05.
** p < 0.001.
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Much of the literature surrounding the anti-cancer properties of
disulﬁram focuses on its interaction with copper, particularly as a
disulﬁram-copper complex [6,24]. In contrast, the effects of zinc on
the drugs toxicity are under-reported, despite knowledge that this
metal is dysregulated in breast cancer cells [15]. The aim of this
study was to determine the role of intra- and extracellular zinc in
the anti-breast cancer properties of disulﬁram. We demonstrated
that under normal growth conditions the drug is able to selectively
kill MCF-7 and BT474 breast cancer cell lines, whilst having no
effect at physiologically relevant concentrations on T47D, MDA-
MB-231 and the non-cancerous breast epithelial MCF-10A cell line.
In disulﬁram sensitive cells a biphasic cell viability proﬁle was
produced, manifest at concentrations between 5 and 20 mM. The
biphasic response has, to varying extents, previously been implied
in other studies involving breast [25] and other cancerous cell lines
[1], however the underlying cause and its clinical signiﬁcance
remains to be determined. To investigate this further we examined
the time dependent toxicity of disulﬁram at concentrations within
this biphasic range, and demonstrated that the response is due to
recovery of initially affected cells. This effect is highly time
dependent and may explain why this is frequently reported in the
literature at time points greater than 24 h [1,25,26], however to
our knowledge, no studies have investigated the sensitivity of cells
to disulﬁram at shorter (<8 h) time points.
Studies have shown that supplementing media with zinc to
increase intracellular levels, presumably through zinc channels,
induces oxidative toxicity [14] and inhibits NFkB signaling
[27]. Our ﬁndings demonstrate that under normal conditions
(complete media) disulﬁram selectively increases intracellular
zinc in breast cancer cells and this may have numerous cellular
effects with some leading to toxicity. However, the fact that
disulﬁram resistant cells (MDA-MB-231) are sensitive to the zinc
loading activity of disulﬁram suggests a complex link between
viability and intracellular zinc. It is also apparent that ionophore-
independent mechanisms could contribute to disulﬁram cytotox-
icity, as 1 mM disulﬁram did not show a measurable increase in
intracellular zinc levels in MCF-7 cells, however produced >50%
decrease in cell viability. Previous studies have demonstrated that
disulﬁram releases zinc from proteins [28], raising the possibility
that the source of this metal which accumulates inside drug
treated cells may be from intracellular proteins. However, our
studies show that the ability of the drug to increase intracellular
zinc is dependent on the availability of extracellular levels of this
metal, supporting the hypothesis that the drug is acting as a zinc
ionophore. This ﬁnding could have far reaching clinical conse-
quences as comparative studies between cancerous and non-
cancerous breast tissue from the same patient have shown that the
latter has elevated zinc levels [15]. Tumors may therefore provide a
more favorable environment for disulﬁram to induce zinc-
associated toxicity by providing an increased source of zinc for
the drug to exert its ionophore action.The observation that disulﬁram is able to increase endo-
lysosomal zinc levels is previously unreported, and may have
important implications in its selective anti-breast cancer effect. The
possibility exists that the cell utilizes certain compartments as an
intracellular pool of zinc [29], and we hypothesize that breast cancer
cells treated with disulﬁram experience a sudden increase in zinc
which the cell compartmentalizes to endo-lysosomes in an attempt
to buffer the excess. The cytoprotective distribution of excess zinc to
lysosomes has recently been reported, however high lysosomal
zinc sequestration was also able to induce apoptosis when lysosomal
release mechanisms were compromised [30]. Additionally, in-
creased lysosomal storage of zinc has been observed in cancer cells
treated with clioquinol, another zinc ionophore [31]. High zinc levels
led to lysosomal dysfunction, causing the release of lysosomal
enzymes to the cytoplasm and consequently apoptosis. Whether
this represents a mechanism underlying disulﬁram action here is not
yet known but currently under investigation. It has been established
that intracellular localization of endo-lysosomal components is
integral to their cellular function, for example starvation and altered
intracellular pH have been shown to redistribute lysosomes
between perinuclear and peripheral regions of the cell [32,33]. Here,
we show that disulﬁram is able to alter the sub-cellular localization
of endo-lysosomal components and by this mechanism may alter
their function, providing more evidence that the lysosomal
sequestration of zinc may promote lysosomal disruption. Other
studies have noted that increased lysosomal zinc is required for
inducing autophagy in tamoxifen treated MCF-7 cells [34]. Despite
increasing lysosomal zinc levels, we found that disulﬁram did not
induce autophagy.
It has previously been reported that the addition of copper
[5,9,24,25], zinc [9] and other metal ions such as cadmium [35] to
the extracellular media increases the potency of disulﬁram across a
range of cancer cell types. The incubation of copper to remove the
biphasic phase has previously been reported [25] but here we
demonstrate that zinc supplement has the same effect. Critically
the ability of either metal ion to remove the biphasic peak implies
that the toxicity of disulﬁram at 10 mM is limited by the
availability of copper and zinc in the media. When considering
the ability of disulﬁram to increase intracellular zinc and copper
levels, the possibility exists that an increase in extracellular copper
and zinc allows disulﬁram to transport more of these metal ions
into the cell, which accounts for the increased toxicity at this
concentration. The low concentrations of either copper and zinc
required to increase disulﬁram potency, suggest that increasing
the availability of either metal ion could be achievable in vivo with
oral supplements to enhance the cytotoxic effects of the drug.
However, data with the MCF-10A cell line suggests that such
supplementation may adversely alter the selectivity of the drug for
breast cancer cells and could cause non-speciﬁc toxicity.
In vivo disulﬁram is rapidly and extensively metabolized in a
systemic manner; the ﬁrst degradation product is DDC and this
metabolite is thought to be a major contributor in the clinical
effects of the drug [36]. DDC has been shown to have toxicity
H.L. Wiggins et al. / Biochemical Pharmacology 93 (2015) 332–342342against breast cancer cells in vitro and increases intracellular
copper in other model systems [7,37]. Additionally, a clinical trial
has shown that adjuvant DDC is able to increase survival in
patients at high risk of metastatic breast cancer [38]. We show here
that DDC, albeit to a lesser extent than disulﬁram was also able to
increase intracellular zinc levels and this may be a mechanism
behind its increased cytotoxicity in the presence of high
extracellular levels of these metal ions.
Measurable cytotoxicity <100 mM, and zinc ionophore activity
of the new disulﬁram analog, FS03EB, was only observed with zinc
supplementation. This provides a direct link between zinc
ionophore activity and cytotoxicity, and supports our hypothesis
that the observed toxicity proﬁles for disulﬁram, DDC and FS03EB
relate to their capacity to increase intracellular zinc. Overall we
propose that extracellular zinc levels and ionophore activity
should be given higher prominence when discussing the effects of
disulﬁram on cancer cells.
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